



BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T : 022- 41840550 / 40037603

F : +91 22 27814204

E : sales@bluejethealthcare.com

CIN NO. : U99999MH1968PLC014154

May 25, 2026

To,

BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	National Stock Exchange of India Limited "Exchange Plaza" Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
--	--

Sub: Analysts/Investors Presentation on Financial Results for the quarter and Financial Year ended March 31, 2026

Dear Sir / Ma'am,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Analysts/Investors Presentation on the Financial Results for the quarter and Financial Year ended March 31, 2026.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

Sweta Poddar
Company Secretary & Compliance Officer

Unit I

3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax : +91 251 2280567

Unit II

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. Tel. : +91 8956363877/8956363878

Unit III

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294

Email : info@bluejethealthcare.com / Website : www.bluejethealthcare.com

Investor Presentation

Q4 & FY26



Disclaimer



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Blue Jet Healthcare Ltd.



Table of Content



- 1 Q4 & FY26 Financials
- 2 Company at a Glance
- 3 Contrast Media Intermediates
- 4 High Intensity Sweeteners
- 5 Pharma Intermediates & API
- 6 R&D Capabilities
- 7 Growth Strategy
- 8 Management and Board of Directors





1

Q4 & FY26 Financials

Q4 FY26 vs Q3 FY26 (QoQ) Earnings Highlights



Financial Highlights

- ✓ **Revenue from Operation** in Q4 FY26 is Rs. 2,347 mn, EBITDA Rs. 713 mn (30% Margin) and PAT Rs. 643 mn (27% Margin)
- ✓ **Revenue from Operation** in Q3 FY26 was Rs. 1,924 mn, EBITDA Rs. 469 mn (24% Margin) and PAT Rs. 402 mn (21% Margin)
- ✓ **QoQ comparison**, Revenue from operations increased by 22%, EBITDA increased by 52% [Rs 244 mn] and PAT increased by 60% [Rs 241 mn] during Q4 FY26.
- ✓ **The increase in Revenue from Operations** during current quarter is due to higher sales of Advance Contrast media.
- ✓ **Gross Margin** for Q4 FY26 was at 56%, higher compared to Q3 FY26 (52%), mainly driven by favourable product mix and higher sales of Contrast media intermediates.
- ✓ **EBIDTA Margin** stands at 30% for the quarter, higher due improved gross margin . Lower employee cost and benefit of higher sales volume & operating leverage.



Q4 FY26 vs Q4 FY25 (YoY) Earnings Highlights



Financial Highlights

- ✓ **Revenue from Operation** in Q4 FY26 is Rs.2,347 mn, EBITDA Rs. 713 mn (30% Margin) and PAT Rs. 643 mn (27% Margin)
- ✓ **Revenue from Operation** in Q4 FY25 was Rs. 3,404 mn, EBITDA Rs. 1,400 mn (41% Margin) and PAT Rs. 1,101 mn (32% Margin)
- ✓ **YoY comparison**, Revenue from operations decreased by 31%, EBITDA decreased by 49% [Rs 687 mn] and PAT decreased by 42% [Rs. 458 mn] during Q4 FY26, due to negligible sales of one of our molecules in the PI vertical. The revenue performance reflects timing-related order phasing in select PI accounts, along with customer-side inventory normalization.
- ✓ **We maintain strong visibility** on the underlying demand and expect normalization to reflect in upcoming quarters
- ✓ **Gross Margin** for Q4 FY26 was at 56% Vs 55% in Q4 FY25, and was stable owing to strong growth reflected in Contrast media Business



FY26 Earnings Highlights



Financial Highlights

- ✓ **Revenue from Operation** for FY26 is Rs. 9,473 mn, EBITDA Rs. 2,941 mn (31% Margin) and PAT Rs. 2,478 mn (26% Margin)
- ✓ **Revenue from Operation** for FY25 was Rs 10,300 mn, EBITDA Rs. 3,777 mn (37% Margin) and PAT Rs. 3,052 mn (30% Margin)
- ✓ **YoY comparison**, Revenue from operations **decreased by 8%**, EBITDA **decreased by 22%** [Rs. 836 mn] and PAT **decreased by 19%** [Rs. 574 mn] during FY26. The decline in Revenue from Operations in FY26 is primarily due to **lower sales in the PI & API segment; however, robust growth in Contrast Media partially offset the decline.**
- ✓ **EBITDA Margin** decreased from 37% to 31%, primarily due to increase in certain operating costs coupled with lower sales volumes.
- ✓ **Gross Margin** for FY26 is at 54% Vs FY25 at 55%. The margins have remained stable.
- ✓ **Other income** increased in FY26 to Rs. ~687 mn from Rs. ~463 mn, mainly driven by foreign exchange gains .



FY26 Earnings Highlights



Business Updates

- ✓ **Vizag Project ground-breaking ceremony completed** and project activities have commenced
- ✓ **R&D Centre Hyderabad civil construction at Hyderabad commenced** – expected to be completed on or before **September 2026 – Hiring of Key Resources Initiated**
- ✓ **Pharma Intermediate [PI] de-stocking and inventory normalization completed by customer ; Robust revenues expected backed by orders from this segment in the coming quarters**
- ✓ **Received trial orders in Advanced Contrast Media** from a new Japanese customer



Q4 FY26 Vs Q4 FY25 Financial Performance – Key Metrics



Revenue from Operations** – Growth Trends

(Rs Mn)

YoY Growth:

23.8%


90.7%

-98.8%

-90.5%


-31.2%

■ Q4 FY25 ■ Q4 FY26




EBITDA Profile


■ EBITDA ○ EBITDA Margin (Rs Mn)



■ PAT ○ PAT Margin (Rs Mn)



■ EPS (Rs)







- *Others include spent oils and industrial mix solvents and R&D services .
- **Excludes Other Operating Revenue.

FY26 Vs FY25 Financial Performance – Key Metrics



Revenue from Operations** – Growth Trends

(Rs Mn)



- *Others include spent oils and industrial mix solvents and R&D
- **Excludes Other Operating Revenue

Profit and Loss Statement




Particulars (Rs. Mn)	Q4 FY26	Q3 FY26	QoQ	Q4 FY25	YoY	FY26	FY25	YoY
Revenue from Operations	2,347	1,924	22.0%	3,404	-31.1%	9,473	10,300	-8.0%
Cost Of Goods Sold	1022	928		1,535		4,358	4,612	
Gross Profit	1,325	996	33.0%	1,870	-29.2%	5,115	5,688	-10.1%
<i>Gross Margin</i>	<i>56.4%</i>	<i>51.7%</i>		<i>54.9%</i>		<i>54.0%</i>	<i>55.2%</i>	
Employee benefits expenses	185	191		160		735	610	
Other expenses	427	336		310		1,439	1,300	
Total Expenses	1,634	1,455		2,005		6,532	6,523	
EBITDA	713	469	52.0%	1,400	-49.1%	2,941	3,777	-22.1%
<i>EBITDA Margin</i>	<i>30.4%</i>	<i>24.4%</i>		<i>41.1%</i>		<i>31.0%</i>	<i>36.7%</i>	
Depreciation and amortization	65	60		49		240	178	
PBIT	877	541	62.1%	1,472	-40.4%	3,388	4,062	-16.6%
Exceptional Items	-	-		-		-	-	
Finance costs	6	3		0		62	1	
Other Income	229	132		122		687	463	
PBT	871	538	62.1%	1,472	-40.8%	3,325	4,061	-18.1%
Tax Expense	228	136		371		847	1,009	
PAT	643	402	60.2%	1,101	-41.6%	2,478	3,052	-18.8%
<i>PAT Margin</i>	<i>27.4%</i>	<i>20.9%</i>		<i>32.3%</i>		<i>26.2%</i>	<i>29.6%</i>	

Financial Performance over the years – Key Metrics




Revenue from Operations** – Growth Trends


(Rs Mn)



EBITDA Profile



PAT Profile



- *Others include spent oils, Industrial mix solvents and R&D
- **Excludes Other Operating Revenue

Financials for the last five years



Summary Statement of Profit and Loss

Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	4,989	6,835	7,210	7,116	10,300	9,473
Other Income	89	194	240	289	463	687
Total Revenue	5,078	7,029	7,449	7,404	10,762	10,160
Cost of Materials consumed	1,695	2,875	3,360	3,144	4,612	4,358
Employee benefits expenses	290	330	419	532	610	735
Finance costs	53	33	14	2	1	62
Depreciation and amortization	197	221	251	281	178	240
Other expenses	945	1,137	1,240	1,148	1,300	1,439
Total Expenses	3,178	4,597	5,283	5,106	6,701	6,834
Exceptional Items	(53)	-	-	(97)	-	-
PBT	1,847	2,432	2,166	2,200	4,061	3,325
Tax Expense	489	616	566	563	1,009	847
PAT	1,358	1,816	1,600	1,637	3,052	2,478


Summary Statement of Assets and Liabilities

Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	FY26
I. Assets						
Property, plant and equipment	1,188	1,185	1,282	1,491	2,596	2,529
Other non-current assets	275	466	688	2,041	1,519	4,312
Total non-current assets	1,463	1,651	1,970	3,532	4,116	6,841
Inventories	1,177	1,050	1,257	1,298	2,639	1,874
Trade receivables	1,440	2,274	2,394	1,769	3,495	3,390
Investments (Current)	368	938	1,893	2,355	1,867	2,267
Cash and cash equivalents	611	754	654	410	330	609
Other current assets	304	467	453	1,224	1,728	1,430
Total current assets	3,900	5,483	6,651	7,056	10,059	9,570
Total assets	5,363	7,134	8,621	10,588	14,175	16,412
II. Equity and liabilities						
Total equity	3,398	5,215	6,815	8,452	11,331	13,599
Borrowings	287	-	-	-	-	-
Other non-current liabilities	47	173	67	77	285	538
Total non-current liabilities	334	173	67	77	285	538
Current borrowings	229	-	-	-	-	-
Trade payables	595	565	538	303	891	569
Other current liabilities	807	1,180	1,201	1,757	1,669	1,706
Total current liabilities	1,631	1,745	1,739	2,060	2,559	2,275
Total liabilities	1,965	1,918	1,806	2,136	2,844	2,813
Total equity and liabilities	5,363	7,134	8,621	10,588	14,175	16,412

Shareholder Information



Shareholding as on 31st March 2026



Share Information as on 31st March 2026

NSE Ticker	BLUEJET
BSE Ticker	544009
Market Cap (INR Cr) (BSE)	5,676
% free-float	20.2%
Free-float market cap (INR Cr)	1,146
Cash & Cash Equivalents + Treasury Investment (INR Mn) (As on 31st March 2026)	3,619
Shares Outstanding	17,34,65,425
3M ADTV (Shares)*	7,54,980
3M ADTV (INR Cr)*	29.8
Industry	Pharmaceuticals


*Source: NSE & BSE
 ADTV (Shares): Average Daily Traded Volume
 ADTV (INR Cr): Average Daily Traded Value



2

Company at a Glance

Our Journey



Who we are



A **specialty pharmaceutical** and **healthcare ingredient** and **intermediate** company, offering **niche products** with an approach of “**Collaboration, Development, Manufacturing**” to **CDMO** business.



Blue Jet Healthcare at a glance



Key metrics

51¹ Commercialized product portfolio (FY26)	1,175.60 KL reaction capacity across 3 facilities (FY26)	INR 9,473.2 mn Revenue (FY26) (13.7% FY21-26 CAGR)	INR 2,940.99 mn EBITDA (FY26) (31.0% margin)
24.9% ROCE (FY26)	19.9% ROE (FY26)	3.75x Fixed Asset Turnover (FY26)	INR 3,619 mn Cash and Cash Equivalents + Treasury Investments (as of 31 st March 2026)

Business Overview



1. Includes 19, 4, and 28 commercialized products for contrast media, high intensity sweeteners, and pharma intermediates and APIs respectively
Source: Company Information

Overview of our Product Categories



Overview

End uses

of commercialized products (FY26)

Revenue contribution (FY26)

Client relationships

Contrast Media Intermediates

- Contrast media are agents used in medical imaging to enhance the visibility of body tissues
- Company supplies critical starting intermediate and several advanced intermediates




X-ray & CT Scan



MRI Scan

19



- Top 4 players accounts for ~75% global market share¹
- 4–27 years of relationship with the 3 of the largest manufacturers .


High Intensity Sweeteners

- High-intensity sweetener business involves development, manufacture and marketing of saccharin and its salts

- Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds



4



- Offers high-intensity sweeteners to over 300 customers globally
- Marquee customers – in FMCG and Agro chemical Space


Pharma Intermediates & APIs

- Collaboration with innovator pharmaceutical companies and multi-national generic companies
- Provides intermediates that serve as pharmaceutical building blocks for APIs in chronic therapeutic areas

- Chronic therapeutic areas such as cardiovascular system (“CVS”), central nervous system (“CNS”), oncology etc



28



- Markets predominantly in regulated markets
- Over 56 customers globally of which 40 in India

Note: ¹ In each of MAT June 2019, 2020, 2021, 2022 and 2023

Source: Company information, IQVIA report dated October 9, 2023 (“Industry Report”)



3

Contrast Media Intermediates

Overview of Contrast Media and its growth drivers



What is contrast media?

- Chemical agents that **enhances the contrast of an imaging modality** in diagnostic imaging, thereby **aiding diagnosis of diseases**
- Once inside the human body, selectively and temporarily taken up by different body tissues
- **Enhance the images, leading to better visualizations of the tissues and organs**

Types of contrast media

- **X-ray / Computed Tomography (CT) contrast agents:** Iodine-based contrast media agents
- **Magnetic Resonance Imaging (MRI) contrast agents:** Gadolinium-based agents
- **Ultrasound (USG) agents:** Stabilized microbubble-based contrast media agents

Growth drivers for contrast media

Growing population and changing demographics

(65 yrs.+) estimated to increase from 6.9% of the total world population in 2000 to 10.4% by 2025¹



Growing prevalence of lifestyle diseases

Such as diabetes, physical inactivity, obesity, etc.



Increased convenience

Through online booking and reporting



Rising healthcare expenditure

Global health expenditure grew at 3.9% CAGR from 2000–17



Focus on early diagnostics

Driven by advancement in diagnostic technologies and growing public awareness



Increasing demand for preventive healthcare


Driven by increased awareness and rising curative costs




The global Contrast Media industry is highly concentrated




Global Medical Imaging Market (USD Bn)




Global Contrast Media Formulation Market Revenue (USD Bn)




Revenue Share of Contrast Agent type, 2024



Global Contrast Media Formulations Market, Market Share of Top Companies, 2024



Global Contrast Media Intermediates Market Revenue (USD Mn)



- Collectively hold ~75% of the global sales of contrast media formulations¹
- Highly concentrated and dominated by multi-national corporations
- Either forward integrated (have equipment manufacturing) or long-standing relationships with manufacturers

1. June 2019, 2020, 2021, 2022 and 2023

Source: F&S Report

High entry barriers for key intermediates' vendors



Characteristics of the Contrast Media market



Strict internal standards for product impurity / features profile



Stickiness of relationship




Long-term supply contracts

Blue Jet's positioning

- ✓ More than **two decades of experience**
 - ✓ **75%+ of exports** of a selected contrast media intermediate (**5-Amino-N,N'-bis (2,3-dihydroxypropyl) isophthalamide**) from India¹
 - ✓ Strategically **focused on complex chemistry** categories
-
- ✓ Regularly supplying **key starting intermediate** as the building block
 - ✓ Several **functionally critical advanced intermediates**
 - ✓ **4 to 27** years with 3 of the largest contrast media manufacturers in the world, directly
-
- ✓ **Medium to long term supply contracts** with customers
 - ✓ **~70% of total sales** backed by **contracted sales volumes**²
 - ✓ **Products qualified, approved and validated**

Contrast Media Intermediate product category performance



Note: ¹ In each of the Financial Years 2020, 2021 and 2022; ² For Financial Years 2021, 2022, 2023 and three months ended 1Q 2023
Source: Industry Report

Source: Company information

Continue to forward integrate into more advanced intermediates for Contrast Media



Strong product development and process optimization capabilities underpinned by **in-house R&D capabilities**



Focus on molecules with **customer interest** and **strategy** in either **outsourcing or alternate sourcing** the next stage of advanced intermediates



Key starting intermediate as building block in 2000 to **19 additional advanced intermediates** as of FY26



Further **improving chemistry** capabilities in close **synergy** with our customers (**4 to 27** years with 3 of top 4 players directly)

Key benefits

Capture **larger wallet share** with existing customers



Higher realization and profitability per unit



Potential of **moving up the value chain**





4

High Intensity Sweeteners

Blue Jet's positioning in High Intensity Sweetener



Blue Jet's positioning

Products



- Adherence to **strict internal standards** to ensure **consistency in quality, performance, taste, and impurity profile**
- **Multiple products and applications** enabling to cater a **diverse customer base**

Compliance, GMP, supply chain reliability




- **Have received US-FDA inspection report**
- **Semi-automated manufacturing facility**
- **Strong product development and process optimization capabilities**

Customers



- Offers high-intensity sweeteners to over **300 customers globally**
- Focus on **marquee customers** across various sub-sectors
- **Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds**

High Intensity Sweeteners product category performance




Sources: Company information


Global High Intensity Sweeteners Market



Global Artificial Sweetener Market Revenue (USD Mn)




Global High-intensity Sweetener Market, Revenue share by segments, 2024




Global Sucralose Market Revenue (USD Mn)

CAGR, 2019-2024 - 5.2%
CAGR, 2024-2029F - 5.7%



Global Saccharin Market Revenue (USD Mn)

CAGR, 2019-2024 - 7.9%
CAGR, 2024-2029F - 8.5%





5 Pharma Intermediates & API

Trends and features of the Pharma Intermediates and APIs Product Category



Key trends in Pharma Intermediates and CDMO market

Increased propensity to outsource manufacturing of intermediates & APIs

- Enables **asset light model** and ability to focus on development of **novel products for venture capital backed start-ups**
- Provides **cost advantages** and **supply chain efficiencies**

De-risking dependence on China by global API and formulations players

- Concerns around specific APIs made in China, accentuated with Covid-19
- China **implemented stricter regulations** and witnessed rising wage costs

Self sufficiency with import substitution

- Government initiatives such as **PLI schemes** and **bulk drug parks**
- Growth driven by **proven skills, educational systems, supply chain reliability, and IP protection**

The growth in the global pharmaceuticals market

- Launch of novel therapies (including biologics and personalized therapies)
- Expansion of existing therapies in several geographies
- Growing demand for generic medicines

Revenue and capacity utilization predictability for the CDMO

- Customers prefer close partnerships with CDMO driven by
 - Confidentiality of the projects
 - Novelty of the underlying chemistry and need for custom-development

Features of a typical arrangement to supply of intermediates to innovators of NCEs

Higher realizations per unit sold

- Key criteria for selection of CDMO include track record in the chemistry and similar therapy areas
- Competitive cost is not the most important consideration

Overview of Blue Jet's Pharma Intermediates and APIs Product Category



Salient features

- Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity sweetener business
- Key focus areas include high-value pharma intermediates and APIs
 - In chronic therapeutic areas
 - Import substitution market
- Benefit from collaboration with innovator companies because typical technology transfer reduces the development risk



Client profile


- Innovator pharmaceutical companies and multi-national generic pharmaceutical
- Over 40 customers in India, and 16 globally across Europe, North America, South America, and Asia



Therapeutic areas

- Cardiovascular system ("CVS")
- Oncology
- Central nervous system ("CNS")


Pharma Intermediate and APIs product category performance




CDMO Potential in API for Indian Players




Global CDMO Market by Modality (USD Bn)




Global CDMO Market Revenue (USD Bn)




Global API CDMO Market by Innovation Type (USD Bn)



Indian CDMO Market Revenue (USD Bn)



Cost of R&D and Manufacturing - Comparison of USA versus other regions, 2024



Source: F&S Report

Note: Relative numbers indexed against the USA, based on Industry KOL estimates

Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category



Focus on three niche areas in providing CDMO services



Investigational new drugs and new chemical entities (NCEs)

Develop advanced intermediates for NCEs under trials for US-FDA approvals



Drugs that are still under patent and not genericized

Offering advanced intermediates to innovators for four active pharmaceutical ingredients (APIs) which are still under patent

- Including two APIs in the oncology sector, one API in the cardiovascular system category and one API in the central nervous system category



Genericized drugs that are still niche

Offering multiple advanced intermediates to a number of large generics companies for chronic illness therapies

Blue Jet's positioning



Leverage long-standing relationships with innovator companies



Process research, analytical research and chemistry capabilities



Continuous focus on product quality



6

R&D Capabilities

Our R&D framework



R&D capabilities across

Process research

Portfolio
evaluation

Process
development

Process scale-up
and validation

Regulatory filings
and approvals

Analytical research

Literature search

Method
development and
optimization

Characterization of
impurities and
standards

Method validation

Non-carry over
studies

Stability/hold-time
studies

Chemistry research

Polymorphism
screening and
optimization

Pharmaceutical salt
screening and
optimization

Cryogenic reactions

High pressure
reactions

High temperature
reactions

Asymmetric
hydrogenation

Enzymatic
transformations

Particle size
distribution studies

Innovative and complex processes

Catalytic
hydrogenation

Iodination

Bromination

Chlorination

Diazotization

Esterification

Hoffman
re-arrangement



Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint

Invested in windmills with installed capacity of 3.3MW



Created carbon sinks through tree plantations



Focus on enhancing energy efficiency



Effluent treatment plants with modern standards of flocculation, clarification and aeration



Minimizing solvents and using recycled solvents and water






7

Growth Strategy

Our strategies





8

Management and Board of Directors

Experienced and visionary management team backed by independent - Board of Directors



Management team



**Akshay Bansarilal
Arora**
Executive Chairman

- Has more than three decades of experience with the Company
- Holds bachelor's and master's degrees in science from University of Mumbai



**Shiven Akshay
Arora**
Managing Director

- Has more than six years of experience with the Company
- Holds a bachelor's degree in business from Bond University, Gold Coast, Australia



Naresh Suryakant Shah
Executive Director, Head
– Marketing

- Has more than three decades of experience in marketing
- Currently also associated as a director of BC Bio Sciences
- Holds a diploma in Chemical Engineering from the Khopoli Polytechnic College, Raigad



**Ganesh
Karuppunnan**
Chief Financial Officer

- Previously worked with Philips Electronics, Dr. Reddy's Laboratories, Granules as CFO
- Associate member of Institute of Chartered Accountants of India since 1988



**Vimalendu Kumar Singh
(V.K. Singh)**
Chief Operating Officer

- Previously worked with Strides Pharma, Emcure Pharmaceuticals, RPG Life Sciences, and Ranbaxy Laboratories
- Has a bachelor's degree in chemical engineering from IIT Kanpur and a master's programme from IIFT, New Delhi



Chandrashekar Parenky
President – Research and
Development

- Previously worked at Amoli Organics and Kores (India) as CEO
- Holds a doctorate of philosophy in science from the University of Bombay and a master's degree from Birla Institute of Technology & Science

Experienced and visionary management team backed by independent Board of Directors (cont'd)



Management team (cont'd)



Popat B Kedar
Executive Director

- Holds a Bachelor's and Master's degree in Science, specializing in Inorganic Chemistry from Shivaji University, Kolhapur.
- Has over 34 years of experience as a Plant Manager, previously working with Infotech Pharma Pvt. Ltd., Godavari Drugs Pvt. Ltd., and Sara Research Centre.
- Associated with the company since July 2005 and served as a Director at Blue Jet Healthcare Limited from December 31, 2020, to February 1, 2022.



Sweta Poddar
Company Secretary and
Compliance Officer

- Has experience of over a decade as a company secretary
- Associated with Chinar Chemicals Private Ltd. and Aarey Drugs and Pharmaceuticals Ltd.
- Holds a bachelors' degree in commerce from the University of Calcutta



**Girish Paman
Vanvari**
Independent Director

- Founder and Partner of Transaction Square LLP and Valuation Square LLP . He is the member of Institute of Chartered accountants of India.
- Has experience in tax, regulatory, and business advisory functions
- Holds a bachelor's degree in commerce from Shri Narsee Monjee College of Commerce and Economics
- Other Directorships held: Tarsons Products Ltd , Aurbindo Pharma Ltd , Himadri Speciality Chemical Ltd, Kolte Patil Developers Ltd



**Preeti Gautam
Mehta**
Independent Director

- Practicing advocate & solicitor and a senior partner of Kanga & Co
- Over 30 years of experience in corporate laws, foreign investments, M&A & PE investments, banking, franchising, and hospitality
- Other Directorships held: Sumitomo Chemicals Ltd, Prpten - E Gov Technologies Ltd, JCB India Ltd



**Divya Sameer
Momaya**
Independent Director

- Holds a bachelor's degree in commerce from the University of Pune
- Partner of D. S. Momaya & Co. LLP and first director of MMB Advisors Private Limited
- Previously worked with BSE Limited and BSEL Infrastructure Realty Limited
- Other Directorships held: GTPL Hathway Ltd, Motilal Oswal Financial Services Ltd, Motilal Oswal Home Finance Ltd



Priyanka Yadav
Independent Director

- Ms. Priyanka Yadav, a Fellow Member of ICSI, holds bachelor's, master's, and law degrees from the University of Mumbai.
- She leads Priyanka Yadav & Associates with 6+ years of experience in corporate laws, NCLT matters, and compliance.
- An expert in listing compliance, IPOs, and corporate restructuring, she advises on governance and legal due diligence.

Thank you!

BLUE JET HEALTHCARE LIMITED



Registered Office

701,702, 7th Floor, Bhumiraj Costarica,
Sector 18, Sanpada, Navi Mumbai Thane
400705, Maharashtra, India



NSE: BLUEJET, **BSE:** 544009

ISIN: INE0KBH01020

Website: www.bluejethealthcare.com

INVESTOR RELATIONS AT



Blue Jet Healthcare Limited

Sanjay Sinha, Deputy Chief Financial Officer
sanjay.sinha@bluejethealthcare.com



Kunal Bhoite
kunal.bhoite@in.ey.com

Advait Bhadekar
advait.bhadekar@in.ey.com